 Icosavax Inc NASDAQ: ICVX has announced topline interim results from its ongoing Phase 12 trial of IVX-411, a VLP vaccine candidate displaying the SARS-CoV-2 receptor-binding domain RBD. In the naïve setting, adjuvant effect on immunogenicity and a dose-response were. 